Drugmakers increased the list prices of their drugs far beyond the inflation rate between 2017 and the first quarter of 2019, California found in a first-of-its kind study of 1,020 drugs based on the state’s mandatory wholesale price reporting requirements.

The average increase in the wholesale acquisition cost — the manufacturers’ list prices for wholesalers or direct purchasers — was 25.8 percent between 2017 and Q1 2019, according to the Office of Statewide Health Planning and Development.

The least expensive prescription drugs, priced at under $100, experienced the largest three-year increase of 37.6 percent. The annual inflation rate over the same period was two percent.